UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that the proportion of treatment-naive
non-cirrhotic subjects with Genotype (GT)-1b treated with Daclatasvir (DCV)/Asunaprevir
(ASV)/BMS-791325 who achieve Sustained Virologic response (SVR12), defined as Hepatitis C
virus (HCV) RNA < LOQ target detected or target not detected (LOQ TD/TND) at follow-up Week
12, is significantly higher than SVR12 of current Standard of Care (SOC).